MARKET

SYBX

SYBX

Synlogic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.120
+0.160
+8.16%
Opening 14:31 11/19 EST
OPEN
1.960
PREV CLOSE
1.960
HIGH
2.130
LOW
1.960
VOLUME
76.90K
TURNOVER
--
52 WEEK HIGH
11.43
52 WEEK LOW
1.910
MARKET CAP
68.46M
P/E (TTM)
-1.1616
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SYBX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SYBX News

  • The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
  • Benzinga.6h ago
  • Can Synlogic (NASDAQ:SYBX) Afford To Invest In Growth?
  • Simply Wall St..5d ago
  • Edited Transcript of SYBX earnings conference call or presentation 12-Nov-19 10:00pm GMT
  • Thomson Reuters StreetEvents.6d ago
  • Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.6d ago

More

Industry

Pharmaceuticals
+0.38%
Pharmaceuticals & Medical Research
+0.77%

Hot Stocks

Name
Price
%Change

About SYBX

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
More

Webull offers Synlogic Inc (SYBX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.